NETEC Resource Library

Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field

Contenu

Click for External Resource*


Click to read full article*


*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.


Item Type

Publication

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Was this resource helpful?


Titre

Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field

Sujet

Description

Two phase 2 randomised clinical trials evaluating ChAd3-EBO-Z administered to healthy adults in Cameroon, Mali, Nigeria, and Senegal and healthy children in Mali and Senegal are reported by Milagritos Tapia and colleagues in The Lancet Infectious Diseases. No vaccine-related serious adverse events were observed and adverse events were minimal.

Date

2020-03-19

Citer ce document

Bavari, Sina, and Patrick L. Iversen. 2020. "Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field." The Lancet Infectious Diseases.

Accessibilité

Through subscription on Lancet.

Collection